Argenx SE (ARGX)
Stock Price:
$228.72 USD
0.86 (0.38%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
10.75B |
| Revenue (ttm) |
78.41M |
| Net Income (ttm) |
-183.11M |
| Shares Out |
47.00M |
| EPS (ttm) |
-1.73 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$228.72 |
| Previous Close |
$227.86 |
| Change ($) |
0.86 |
| Change (%) |
0.38% |
| Day's Open |
230.42 |
| Day's Range |
228.01 - 232.90 |
| Day's Volume |
138,252 |
| 52-Week Range |
103.75 - 242.37 |
More Stats
| Market Cap |
10.75B |
| Enterprise Value |
9.26B |
| Earnings Date (est) |
Jul 30, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
47.00M |
| Float |
42.71M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-1.73 |
| FCF / Share |
4.00 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
1.44% |
| Payout Ratio |
n/a |
| Shares Short |
706,169 |
| Short Ratio |
2.36 |
| Short % of Float |
n/a |
| Beta |
1.10 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
69.61 |
| PS Ratio |
137.12 |
| PB Ratio |
8.69 |
| Revenue |
78.41M |
| Operating Income |
-201.85M |
| Net Income |
-183.11M |
| Free Cash Flow |
154.45M |
| Net Cash |
1.49B |
| Net Cash / Share |
31.78 |
| Gross Margin |
100.00% |
| Operating Margin |
-257.44% |
| Profit Margin |
-233.50% |
| FCF Margin |
196.98% |
| ROA |
-11.16% |
| ROE |
-20.51% |
| ROIC |
-27.20% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (21)
| Buy |
16 |
| Overweight |
1 |
| Hold |
4 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$235.64*
(3.03% upside)
Low
147
Current: 228.72
High
290
Target: 235.64
*Average 12-month USD price target from 21 stock analysts.
Financial Performance
Financial numbers in millions EUR.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | 69.78 | 21.48 | 36.42 | 14.71 | 6.85 |
| Revenue Growth | 224.84% | -41.01% | 147.5% | 114.66% | - |
| Gross Profit | 69.78 | 21.48 | 36.42 | 14.71 | 6.85 |
| Operating Income | -180 | -81.85 | -22.93 | -21.42 | -15.61 |
| Net Income | -163 | -66.64 | -28.08 | -21.37 | -15.31 |
| Shares Outstanding | 38.62 | 33.42 | 24.61 | 18.82 | 15.73 |
| Earnings Per Share | -4.22 | -1.99 | -1.14 | -1.14 | -0.97 |
| Operating Cash Flow | 139 | -53.27 | -36.55 | 10.60 | -13.90 |
| Capital Expenditures | -1.60 | -0.62 | -0.35 | -0.84 | -0.27 |
| Free Cash Flow | 137 | -53.90 | -36.89 | 9.76 | -14.17 |
| Cash & Equivalents | 1,336 | 566 | 361 | 97.51 | 42.33 |
| Total Debt | 6.51 | - | - | - | - |
| Net Cash / Debt | 1,329 | 566 | 361 | 97.51 | 42.33 |
| Assets | 1,433 | 578 | 371 | 106 | 45.96 |
| Liabilities | 383 | 40.06 | 25.98 | 42.40 | 8.68 |
| Book Value | 1,051 | 538 | 345 | 63.37 | 37.28 |
Numbers in millions EUR, except per-share numbers.
Company Details
| Full Name |
Argenx SE |
| Country |
Netherlands |
| Employees |
186 |
| CEO |
Tim van Hauwermeiren |
Stock Information
| Ticker Symbol |
ARGX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ARGX |
| IPO Date |
May 18, 2017 |
Description
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer indications; and preclinical products, including ARGX-117 with therapeutic potential in both orphan and large autoimmune inflammatory diseases in and ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation and ARGX-115 for cancer immunotherapy, which are in Phase 1 clinical stages; and ARGX-116 for the treatment of dyslipidemia and ARGX-114 for treating fibrosis, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.